Skip to main content

Table 9 Canadian Cardiovascular Society guidelines for CVD prevention and dyslipidemia management: treatment thresholds and targets based on Framingham Risk Score (FRS)[125]

From: A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

Risk level Initiate therapy if: Primary target LDL-C Alternate target
High • Consider treatment in all • ≤2 mmol/L, or • Apo B ≤0.8 g/L
FRS ≥20%   • ≥50% ↓ in LDL-C • Non HDL-C ≤2.6 mmol/L
Intermediate • LDL-C ≥3.5 mmol/L • ≤2 mmol/L,or • Apo B ≤0.8 g/L
FRS = 10%-19% • For LDL-C <3.5 consider if: • ≥50% ↓ in LDL-C • Non HDL-C ≤2.6 mmol/L
    → Apo B ≥1.2 g/L, or   
    → Non-HDL-C ≥4.3 mmol/L   
Low • LDL-C ≥5.0 mmol/L • ≥50% ↓ in LDL-C  
FRS <10% • Familial hypercholesterolemia   
  1. Adapted from Anderson et al., 2013 [125].
  2. FRS Framingham Risk Score, HDL-C high-density lipoprotein cholesterol, LDL-C, low-density lipoprotein cholesterol, apo B apolipoprotein B.